LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

4.62 -4.35

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.5600000000000005

Max

4.75

Galvenie mērījumi
By Trading Economics
Ienākumi	672K -877K
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	671K -877K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-73K 18M
Iepriekšējā atvēršanas cena	8.97
Iepriekšējā slēgšanas cena	4.62

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. nov. 23:38 UTC

Peļņas

OCBC Posts Steady Third-Quarter Net Profit, Drop in Net Interest Income

2025. g. 6. nov. 23:00 UTC

Peļņas

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts -- Update

2025. g. 6. nov. 22:19 UTC

Peļņas

Galvenie tirgus virzītāji

Block Shares Slide After 3Q Results Miss Estimates

2025. g. 6. nov. 21:53 UTC

Peļņas

Macquarie's First-Half Profit Grows 2.7%, Missing Forecasts

2025. g. 6. nov. 23:45 UTC

Peļņas

Wheaton Precious Metals 3Q Sales $476M >WPM

2025. g. 6. nov. 23:45 UTC

Peļņas

Wheaton Precious Metals 3Q Adj EPS 61.8c >WPM

2025. g. 6. nov. 23:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. nov. 23:45 UTC

Tirgus saruna

Nikkei May Fall After U.S. Tech Stocks Drop

2025. g. 6. nov. 23:45 UTC

Peļņas

Wheaton Precious Metals 3Q EPS 80.7c >WPM

2025. g. 6. nov. 23:38 UTC

Tirgus saruna

Gold Edges Higher Amid Worrisome Signs for U.S. Economy -- Market Talk

2025. g. 6. nov. 23:15 UTC

Peļņas

Kakao 3Q Net Profit Beat FactSet-Compiled Consensus

2025. g. 6. nov. 23:14 UTC

Peļņas

Kakao 3Q Net KRW192.86B Vs. Net KRW78.51B >035720.SE

2025. g. 6. nov. 23:14 UTC

Peļņas

Kakao 3Q Oper Pft KRW208.05B Vs. Pft KRW130.53B >035720.SE

2025. g. 6. nov. 23:13 UTC

Peļņas

Kakao 3Q Rev KRW2.087T Vs. KRW1.921T >035720.SE

2025. g. 6. nov. 23:08 UTC

Peļņas

Oversea-Chinese Banking Corp. 3Q Total Income S$3.80B Vs. S$3.80B >O39.SG

2025. g. 6. nov. 23:08 UTC

Peļņas

Oversea-Chinese Banking Corp. 3Q Noninterest Income S$1.57B Vs. S$1.37B >O39.SG

2025. g. 6. nov. 23:07 UTC

Peļņas

Oversea-Chinese Banking Corp. 3Q Net S$1.98B Vs. Net S$1.97B >O39.SG

2025. g. 6. nov. 23:07 UTC

Peļņas

Suzano 3Q Rev BRL12.2B >SUZ

2025. g. 6. nov. 22:47 UTC

Iegādes, apvienošanās, pārņemšana

Wheaton Precious Metals to Pay Waterton Gold $670M Up Front

2025. g. 6. nov. 22:47 UTC

Iegādes, apvienošanās, pārņemšana

Wheaton Precious Metals to Buy Gold Stream on Spring Valley Project Located in Nevada >WPM

2025. g. 6. nov. 22:45 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific and Norfolk Southern Provide Supplemental Disclosures to Joint Proxy Statement About Merger

2025. g. 6. nov. 22:25 UTC

Iegādes, apvienošanās, pārņemšana

At Bank of America's Investor Day, M&A Hints, Would-Be CEOs, and AI Pitches -- Barrons.com

2025. g. 6. nov. 22:13 UTC

Peļņas

Fairfax Financial 3Q Rev $8.27B >FFH.T

2025. g. 6. nov. 22:02 UTC

Peļņas

Century Aluminum 3Q Sales $632.2M >CENX

2025. g. 6. nov. 22:02 UTC

Peļņas

Century Aluminum 3Q Adj EPS 56c >CENX

2025. g. 6. nov. 21:53 UTC

Peļņas

DraftKings Stock Sinks on Disappointing Results -- Barrons.com

2025. g. 6. nov. 21:52 UTC

Iegādes, apvienošanās, pārņemšana

Universal Display: Portfolio Includes More Than 300 Issued and Pending Patents Worldwide, Covering More Than 110 Unique Patent Families >OLED

2025. g. 6. nov. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Universal Display Corp to Acquire Emissive OLED Patent Assets From Merck KGaA, Darmstadt, Germany

2025. g. 6. nov. 21:50 UTC

Tirgus saruna

Peļņas

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 6. nov. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.